JP2023544683A5 - - Google Patents

Info

Publication number
JP2023544683A5
JP2023544683A5 JP2023515813A JP2023515813A JP2023544683A5 JP 2023544683 A5 JP2023544683 A5 JP 2023544683A5 JP 2023515813 A JP2023515813 A JP 2023515813A JP 2023515813 A JP2023515813 A JP 2023515813A JP 2023544683 A5 JP2023544683 A5 JP 2023544683A5
Authority
JP
Japan
Application number
JP2023515813A
Other languages
Japanese (ja)
Other versions
JPWO2022053630A5 (https=
JP2023544683A (ja
JP7834725B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/074964 external-priority patent/WO2022053630A1/en
Publication of JP2023544683A publication Critical patent/JP2023544683A/ja
Publication of JP2023544683A5 publication Critical patent/JP2023544683A5/ja
Publication of JPWO2022053630A5 publication Critical patent/JPWO2022053630A5/ja
Application granted granted Critical
Publication of JP7834725B2 publication Critical patent/JP7834725B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023515813A 2020-09-10 2021-09-10 ペプチド改変されたaavカプシド Active JP7834725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306005 2020-09-10
EP20306005.8 2020-09-10
PCT/EP2021/074964 WO2022053630A1 (en) 2020-09-10 2021-09-10 Peptide-modified aav capsid

Publications (4)

Publication Number Publication Date
JP2023544683A JP2023544683A (ja) 2023-10-25
JP2023544683A5 true JP2023544683A5 (https=) 2024-09-19
JPWO2022053630A5 JPWO2022053630A5 (https=) 2024-09-19
JP7834725B2 JP7834725B2 (ja) 2026-03-24

Family

ID=72717827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515813A Active JP7834725B2 (ja) 2020-09-10 2021-09-10 ペプチド改変されたaavカプシド

Country Status (11)

Country Link
US (1) US20240209030A1 (https=)
EP (2) EP4211231B1 (https=)
JP (1) JP7834725B2 (https=)
CN (1) CN116096431A (https=)
CA (1) CA3193128A1 (https=)
DK (1) DK4211231T3 (https=)
ES (1) ES2984259T3 (https=)
FI (1) FI4211231T3 (https=)
PL (1) PL4211231T3 (https=)
PT (1) PT4211231T (https=)
WO (1) WO2022053630A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297391A (en) 2020-04-20 2022-12-01 Tenaya Therapeutics Inc An adeno-associated virus with an engineered capsid
EP4314295A1 (en) 2021-03-26 2024-02-07 The Board Of Regents Of The University Of Texas System Nucleotide editing to reframe dmd transcripts by base editing and prime editing
CN117897492A (zh) 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
US20250249052A1 (en) * 2022-04-07 2025-08-07 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
CN116925192B (zh) * 2022-04-12 2025-04-29 合肥星眸生物科技有限公司 一种融合型腺相关病毒及其应用
JP2025524363A (ja) 2022-06-09 2025-07-30 ジェネトン 糖原病iiiの処置のためのn末端短縮型gde
EP4707399A2 (en) 2022-06-10 2026-03-11 Généthon Peptide-modified aav capsid with enhanced muscle transduction efficiency
US20260053923A1 (en) 2022-10-07 2026-02-26 Genethon Immunotherapy of Skeletal Myopathies Using ANTI-FAP CAR-T Cells
EP4609882A1 (en) * 2022-10-12 2025-09-03 CPC Corporation Gene introduction method, gene therapy method, and tissue regeneration method
TW202502803A (zh) 2023-03-10 2025-01-16 美商戴諾治療公司 衣殼多肽及其使用方法
EP4677073A1 (en) 2023-03-10 2026-01-14 Genethon Induction of immune tolerance by aav vector comprising the combination of a liver detargeted capsid and a tandem liver-muscle specific promoter
CN121420060A (zh) 2023-06-29 2026-01-27 吉尼松公司 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
WO2025048709A1 (en) * 2023-08-25 2025-03-06 Agency For Science, Technology And Research Composition and methods for identification of novel aav variants for differentiated gene delivery to cardiomyoctes and/or skeletal myofibers
WO2025133247A1 (en) 2023-12-21 2025-06-26 Genethon Methods for aav vector re-administration
KR102933125B1 (ko) * 2024-02-01 2026-03-04 주식회사 글루진테라퓨틱스 평활근 세포 특이적 유전자 전달이 가능한 아데노연관바이러스 벡터
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2026017727A1 (en) 2024-07-16 2026-01-22 Genethon Alternative barcoding method to assess transduction efficiency of aav vectors
WO2026064428A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026064444A1 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1222673A1 (zh) * 2013-07-12 2017-07-07 The Children's Hospital Of Philadelphia Aav载体和用於抗aav(腺相关病毒)中和抗体的检测
PE20190401A1 (es) * 2016-07-26 2019-03-13 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado
EP3775173A1 (en) 2018-04-05 2021-02-17 Genethon Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
AU2019258830B2 (en) 2018-04-27 2025-12-18 Universität Heidelberg Modified AAV capsid polypeptides for treatment of muscular diseases

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2023544683A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021015450A8 (https=)
BR102021015220A2 (https=)
BR102021015247A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)
BR102021013929A2 (https=)